Awareness of this lag could provide additional rationale for clinicians to evaluate GM-CSF AAb levels in all patients with opportunistic infections who otherwise appear immunocompetent to confirm or rule out an underlying diagnosis of aPAP. This evidence concerns the gene CSF2 and Opportunistic infection.